Alamar Biosciences, Inc.: 5%+ holders

As of November 9, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Alamar Biosciences, Inc. The largest reported stake is Qiming Corporate GP VI, Ltd's, at 10.2%. 6 filings are on record since April 23, 2026 (Schedule 13G, August 11, 2026).

Who owns Alamar Biosciences, Inc.?

Sands Capital Life Sciences Pulse Fund II, L.P. also filed stake reports on 3 other companies ↓

Sell to companies like Alamar Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-13 · Reporting person: Yuling Luo · Sole voting: 3,304,566 · Shared voting: 1,224,152 · Sole dispositive: 3,304,566 · Shared dispositive: 1,224,152 · SCHEDULE 13G, 2026-08-13
• Filing 2026-08-11 · Reporting person: Qiming Corporate GP VI, Ltd · Sole voting: 7,066,573 · Shared voting: 0 · Sole dispositive: 7,066,573 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-11
• Filing 2026-07-07 · Reporting person: Sands Capital Life Sciences Pulse Fund II, L.P. · Sole voting: 0 · Shared voting: 4,230,926 · Sole dispositive: 0 · Shared dispositive: 4,230,926 · SCHEDULE 13D/A, 2026-07-07
• Filing 2026-07-02 · Reporting person: Sherpa Healthcare Fund Ii, L.P. · Sole voting: 3,970,446 · Shared voting: 0 · Sole dispositive: 3,970,446 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-02
• Filed 2026-04-23 · Holder: Illumina Innovation Fund II, L.P. · Percent: 9.6% · SCHEDULE 13D

Alamar Biosciences, Inc. has 6 Schedule 13D or 13G filings on record since 2026-04-23. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Alamar Biosciences, Inc. and the warning signs.

See Alamar Biosciences, Inc.'s free Snapshot Watch Alamar Biosciences, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Alamar Biosciences, Inc. and the records around it.

Alamar Biosciences, Inc. elsewhere on the record

• Leadership changes Sep 2026
• Who owns it

Companies that share a holder

• Sands Capital Life Sciences Pulse Fund II, L.P. also filed stake reports on 3 other companies: Acrivon Therapeutics, Inc. (Aug 2026), Inhibikase Therapeutics, Inc. (Aug 2026), Beta Bionics, Inc. (Aug 2025)

Want the whole picture on Alamar Biosciences, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Alamar Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Alamar Biosciences, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   12 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Alamar Biosciences, Inc. by CUSIP 010911105 and gives its principal executive office as 47071 Bayside Parkway, Fremont, CA 94538 (SCHEDULE 13G, 2026-08-13).

What the percentages are based on

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2026, and is incorporated by reference.Yuling Luo, SCHEDULE 13G, 2026-08-13

Source of funds (Item 3)

The information set forth in Item 3 of the Original Schedule 13D is incorporated herein by reference.Sands Capital Life Sciences Pulse Fund II, L.P., SCHEDULE 13D/A, 2026-07-07

Purpose of Transaction (Item 4)

Illumina Innovation Fund II, L.P.

The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. Nicholas Naclerio is a member of the Issuer's board of directors. In addition, Nicholas Naclerio, in his capacity as a director, may be entitled to receive cash compensation and equity compensation, including stock option or other equity awards, pursuant to the Issuer's non-employee director compensation …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-23; the filing has the rest

Sands Capital Life Sciences Pulse Fund II, L.P.

Item 4 of the Original Schedule 13D is hereby amended and restated in its entirety as follows: The Reporting Persons acquired and hold the Common Stock for investment purposes in the ordinary course of Sands Pulse Fund II's investment activities. Subject to applicable legal requirements or contractual restrictions, one or more of the Reporting Persons may purchase additional securities of the Issuer from time to time in open market or private transactions depending on their evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Persons' ownership of the Issuer's securities, other opportunities available to the Reporting Persons, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, the Reporting Persons may dispose of all or a portion of their securities of the Issuer at any time. Each of the Reporting Persons reserves the right to increase or decrease its holdings on such terms and at such times as each may decide. Consistent with their investment purpose, the Reporting Persons may engage in communications with persons associated with the Issuer, including shareholders of the Issuer, officers of the Issuer and/or members of the board of directors of the Issuer, to discuss matters regarding the Issuer including but not limited to its operations and strategic …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-07; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Alamar Biosciences, Inc.

Who owns Alamar Biosciences, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Alamar Biosciences, Inc.: Qiming Corporate GP VI, Ltd (10.2%, Schedule 13G, filed 2026-08-11), Illumina Innovation Fund II, L.P. (9.6%, Schedule 13D, filed 2026-04-23), Daqing Cai (7.2%, Schedule 13G, filed 2026-07-02), Yuling Luo (6.4%, Schedule 13G, filed 2026-08-13) and Sands Capital Life Sciences Pulse Fund II, L.P. (6.1%, Schedule 13D/A, filed 2026-07-07).

Who are the largest shareholders of Alamar Biosciences, Inc.?

By the share each holder's latest filing reports, the largest holders of Alamar Biosciences, Inc. on this page are Qiming Corporate GP VI, Ltd (10.2%), Illumina Innovation Fund II, L.P. (9.6%) and Daqing Cai (7.2%).

When did Qiming Corporate GP VI, Ltd buy into Alamar Biosciences, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Qiming Corporate GP VI, Ltd on this page is the Schedule 13G, filed 2026-08-11, reporting 10.2%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Alamar Biosciences, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Alamar Biosciences, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Alamar Biosciences, Inc. is mentioned again
• Find former Alamar Biosciences, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes